Sponsor of the Day:
Jerkmate
https://www.drugtargetreview.com/circio-and-acuitas-partner-on-circular-rna-car-t-therapy/2135220.article
Circio and Acuitas partner on circular RNA for in vivo CAR T-cell therapy | Drug Target Review
Apr 15, 2026 - Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T...
drug target reviewvivo carcell therapypartnercircular
https://www.statnews.com/2026/02/09/eli-lilly-buys-orna-therapeutics-in-vivo-car-t/
Eli Lilly to buy Orna Therapeutics, marker of in vivo CAR-T | STAT
Feb 9, 2026 - Eli Lilly will pay up to $2.4 billion for the biotechnology firm, the latest in a string of deals that the pharmaceutical giant has made in the past year.
eli lillyvivo carbuyornatherapeutics
https://briefpharma.com/lilly-bets-7b-on-kelonias-in-vivo-car-t-tech/
Lilly Bets $7B on Kelonia's In Vivo CAR-T Tech
Apr 21, 2026 - Eli Lilly to acquire Kelonia Therapeutics for $3.25B upfront (up to $7B total) to gain in vivo CAR-T platform for multiple myeloma and beyond.
vivo carlillybets7bkelonia
https://www.genengnews.com/sponsored/signal-or-noise-decoding-in-vivo-car-t/
Signal or Noise? Decoding In Vivo CAR T
Apr 1, 2026 - As CAR T moves into complex in vivo systems, defined antibodies and consistent reagents safeguard early biological signals and translational insight.
vivo carsignalnoisedecoding
https://www.pharnexcloud.com/zixun/trz_293672
2026年4.6-4.12全球医药健康重大投融资&交易周报：in vivo CAR-T交易超500亿与Hologic 183亿美元私有化_摩熵医药
上周，全球医药健康投融资与交易市场活跃，重磅并购与大额融资频发。其中，Hologic高达183亿美元的私有化并购案备受瞩目，Opus Genetics与Stipple Bio等前沿技术公司亦斩获超亿美元融资。本文将为您精要梳理本周核心数据，拆解资本在创新赛道与全球市场布局上的新动向。
6 4vivo car
https://www.statnews.com/2026/03/18/azalea-therapeutics-signs-of-success-in-vivo-car-t-therapy/
Biotech startup shows signs of success with in vivo CAR-T therapy| STAT
A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut costs and expand access.
biotech startupshows signsvivo cartherapy statsuccess
https://www.biospace.com/events/cgt-symposium-in-vivo-car-t-innovation
CGT Symposium: In Vivo CAR-T Innovation
Mar 25, 2026 - One‑day symposium to bring together leading experts to discuss the rapidly evolving landscape of in vivo CAR-T.
vivo carcgtsymposiuminnovation
https://createmedicines.com/
Create Medicines | In Vivo Immune Programming with RNA-CAR Therapies
Create Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable, off-the-shelf treatments for...
createmedicinesvivoimmuneprogramming
https://www.pharmavoice.com/news/lilly-kelonia-car-t-cancer-in-vivo/818010/
Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push | PharmaVoice
The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.
carkeloniadealcementsbig
https://jnm.snmjournals.org/content/67/4/601
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo |...
Chimeric antigen receptor (CAR)-T cell therapy has shown limited success in the treatment of solid tumors, reinforcing the need to elucidate the in vivo...
solid tumorslongitudinaltrackinghumancar